Olivier Laureau, President at Servier Foundation and Servier Group, shared a post on LinkedIn:
“I was delighted to officially and personally welcome the Day One Biopharmaceuticals teams to the Servier Group.
This marks an important step for Servier and the beginning of a new scientific, collective and human adventure, bringing together teams that share the same mission and the same values. This integration strengthens our leadership in glioma and represents a major step forward in our Servier2030 ambition in oncology.
By combining all of our expertise, we will further accelerate innovation with a clear objective: to turn science into tangible benefits for patients, particularly for children and families affected by rare cancers.
Welcome to Servier, everyone!”
Other articles about Servier on OncoDaily.